Abstract
In this review, we relate both laboratory and clinical evidence associated with the capacity for estrogen to function as a modulator of nigrostriatal dopaminergic pathology. To accomplish this goal, we have divided this review into three parts. In Part 1, we provide a brief historical perspective of studies that have laid the groundwork for demonstrating the existence of hormonal-nigrostriatal interactions. In Part 2, we focus specifically on laboratory data that show the ability and conditions by which estrogen may function as a neuroprotectant of the nigrostriatal dopaminergic system. Finally, in Part 3, we review the clinical literature related to this issue as a means for consideration of estrogen as a modulator, neuroprotectant, and therapy for Parkinson disease.
Similar content being viewed by others
References
Lichtensteiger, W. (1969). J. Pharmacol. Exp. Ther. 165, 204–215.
Greengrass, P. M. and Tonge, S. R. (1971). J. Pharm. Pharmacol. 23, 897,898.
Jori, A. and Cecchetti, G. (1973). J. Endocr. 58, 341, 342.
Holzbauer, M. and Youdim, M. B. H. (1973). Br. J. Pharmacol. 48, 600–608.
Jori, A., Colturani, F., Dolfini, E., and Rutczynski, M. (1976). Neuroendocrinology 21, 262–266.
Crowley, W. R., O’Donohue, T. L., and Jacobowitz, D. M. (1978). Brain Res. 147, 315–326.
Fernandez-Ruiz, J. J., Hernandez, M. L., de Miguel, R., and Ramos, J. A. (1991). J. Neural Transm. (Gen. Sect.) 85, 223–229.
Becker, J. B. and Ramirez, V. D. (1981). Brain Res. 204, 361–372.
Becker, J. B. and Cha, J.-H. (1989). Behav. Brain Res. 35, 117–125.
Becker, J. B. and Xiao, L. (1994). Neurosci. Lett. 180, 155–158.
Dluzen, D. E. and Ramirez, V. D. (1985). Neuroendocrinology 41, 97–100.
Dluzen, D. E. and Ramirez, V. D. (1990). Brain Res. 536, 163–168.
Levesque, D., Gagnon, S., and Di Paolo, T. (1989). Brain Res. Bull. 24, 281–284.
Di Paolo, T., Falardeau, P., and Morissette, M. (1988). Life Sci. 43, 665–672.
Davis, C. F., Davis, B. F., and Halaris, A. E. (1977). Life Sci. 20, 1319–1332.
Morissette, M. and Di Paolo, T. (1993). Neuroendocrinology 58, 16–22.
Morissette, M., Garcia-Segura, L.-M., Belanger, A., and Di Paolo, T. (1992). Neuroscience 49, 893–902.
Becker, J. B., Robinson, T. E., and Lorenz, K. A. (1982). Eur. J. Pharmacol. 80, 65–72.
Becker, J. B., Snyder, P. J., Miller, M. M., Westgate, S. A., and Jenuwine, M. J. (1987). Pharmacol. Biochem. Behav. 27, 53–59.
Diaz-Veliz, G., Benavides, M. S., Burton, S., Dussaubat, N., and Mora, S. (1999). Pharmacol. Biochem. Behav. 62, 21–29.
Gordon, J. H. and Shellenberger, M. K. (1974). Neuropharmacology 13, 129–137.
Crowley, W. R., O’Donohue, T. L., and Jacobowitz, D. M. (1978). Acta Endocrinol. 89, 20–28.
Becker, J. B. (1999). Pharmacol. Biochem. Behav. 64, 803–812.
Gratton, L. (1960). Union Med. Can. 89, 679–694.
Crane, G. E. (1968). Am. J. Psychiatry 124(Suppl.), 40–48.
Bedard, P., Langelier, P., and Villeneuve, A. (1977). Lancet 2, 1367, 1368.
Nausieda, P. A., Koller, W. C., Weiner, W. J., and Klawans, H. L. (1979). Neurology 29, 1605–1609.
Lal, S. and Sourkes, T. L. (1972). Arch. Int. Pharmacodyn. 199, 289–301.
Nausieda, P. A., Koller, W. C., Weiner, W. J., and Klawans, H. L. (1979). Life Sci. 25, 521–526.
Van Hartesveldt, C. and Joyce, J. N. (1986). Neurosci. Biobehav. Rev. 10, 1–14.
Di Paolo, T. (1994). Rev. Neurosci. 5, 27–42.
Ramirez, V. D., Kim, K., and Dluzen, D. E. (1985). Recent Prog. Horm. Res. 41, 421–472.
Menniti, F. S. and Baum, M. J. (1981). Brain Res. 216, 89–107.
Savageau, M. M. and Beatty, W. W. (1981). Pharmacol. Biochem. Behav. 14, 17–22.
Beatty, W. W., Dodge, A. M., and Traylor, K. L. (1982). Pharmacol. Biochem. Behav. 16, 565–568.
Dluzen, D. E. and Ramirez, V. D. (1989). J. Neuroendocrinol. 1, 285–290.
Brooks, W. J., Jarvis, M. F., and Wagner, G. C. (1989). Res. Commun. Subst. Abuse 10, 181–184.
Freyaldenhoven, T. E., Cadet, J. L., and Ali, S. F. (1996). Brain Res. 735, 232–238.
Ali, S. F. and Freyaldenhoven, T. (1999). In: Chemicals and neurodegenerative disease. Bondy, S. C. (ed.). Prominent Press: Scottsdale, AZ.
Miller, D. B., Ali, S. F., O’Callaghan, J. P., and Laws, S. C. (1998). Ann. NY Acad. Sci. 844, 153–165.
Wagner, G. C., Tekirian, T. L., and Cheo, C. T. (1993). J. Neural Transm. (Gen. Sect.) 93, 67–70.
Yu, Y.-L. and Wagner, G. C. (1994). J. Neural Transm. (P-D Sect.) 8, 215–221.
Yu, L. and Liao, P.-C. (2000). J. Neural Transm. 107, 419–427.
Heller, A., Bubula, N., Lew, R., Heller, B., and Won, L. (2001). J. Pharmacol. Exp. Thera. 298, 769–779.
Gomez-Mancilla, B. and Bedard, P. (1992). Neurosci. Lett. 135, 129–132.
Dluzen, D. E., McDermott, J. L., and Liu, B. (1996). J. Neurochem. 66, 658–666.
Dluzen, D. E., McDermott, J. L., and Liu, B. (1996). Neurotoxicol. Teratol. 18, 603–606.
Dluzen, D. E. (1997). Brain Res. 767, 340–344.
Gao, X. and Dluzen, D. E. (2001). Neuroscience 103, 385–394.
Dluzen, D. E. and McDermott, J. L. (2000). Ann. NY Acad. Sci. 914, 112–126.
Dluzen, D. E. and McDermott, J. L. (2002). Ann. NY Acad. Sci. 965, 136–156.
Grandbois, M., Morissette, M., Callier, M., and Di Paolo, T. (2000). Neuroreport 11, 343–346.
Dluzen, D. E., McDermott, J. L., and Anderson, L. I. (2003). Neurotoxicol. Res. 3, 291–300.
Gajjar, T. M., Anderson, L. I., and Dluzen, D. E. (2003). J. Neural Transm., in press.
Yu, L., Kuo, Y., Cherng, C. G., Chen, H.-H., and Hsu, C.-H. (2002). Neuroendocrinology 75, 282–287.
Anderson, L. I., Leipheimer, R. E., and Dluzen, D. E. (2002). Soc. Neurosci. Abstr., #810.10, 32nd Ann. Mtg.
Dluzen, D. E., McDermott, J. L., and Anderson, L. I. (2001). J. Neuroendocrinol. 13, 618–624.
Yu, L. and Liao, P.-C. (2000). J. Neural Transm. 107, 1139–1147.
Tomas-Camardiel, M., Sanchez-Hidalgo, M. C., Sanchez Del Pino, M. J., Navarro, A., Machado, A., and Cano, J. (2002). Neuroscience 109, 569–584.
Gao, X. and Dluzen, D. E. (2001). Brain Res. 892, 63–69.
Dluzen, D. E., Disshon, K. A., and McDermott, J. L. (1998). In: Advances in neurodegenerative disorders—vol. 1: Parkinson’s disease. Marwah, J. E. and Teitelbaum, H. (eds.). Prominent Press: Scottsdale, AZ.
Dluzen, D. E. (2000). J. Neurocytol. 29, 387–399.
Dluzen, D. E. and McDermott, J. L. (2000). J. Gender Spec. Diff. 3, 36–42.
Dluzen, D. E., Jain, R., and Liu, B. (1994). J. Neurochem. 62, 94–101.
Grandbois, M., Tanguay, B., and Di Paolo, T. (1999). Soc. Neurosci. Abstr. 25, 1595.
Dluzen, D. E. (1996). Brain Res. 715, 113–118.
de la Fuente-Fernandez, R. and Stoessl, A. J. (2002). TINS 25, 302–306.
Quinn, N. P. and Marsden, C. D. (1986). Mov. Disord. 1, 85–87.
Horstink, M. W. I. M., Strijks, E., and Dluzen, D. E. (2003). Adv. Neurol. 91, 107–114.
Kompoliti K., Comella, C. L., Jaglin, J. A., Leurgans, S., Raman, R., and Goetz, C. G. (2000). Neurology 55, 1572–1575.
Zhang, Z. and Roman, G. C. (1993). Neuroepidemiology 12, 195–208.
Tanner, C. M. and Goldman, S. M. (1996). Neurol. Clin. 14, 317–335.
Bower, J. H., Maraganore, D. M., McDonnell, S. K., and Rocca, W. A. (1999). Neurology 52, 1214–1220.
Claveria, L. E., Duarte, J., Sevillano, M. D., et al. (2002). Mov. Disord. 17, 242–249.
Baldereschi, M., Di Carlo, A., Rocca, W. A., et al. (2000). Neurology 55, 1358–1363.
Kuopio, A. M., Marttila, R. J., Helenius, H., and Rinne, U. K. (1999). Neurology 52, 302–308.
Elbaz, A., Bower, J. H., Maraganore, D. M., et al. (2002). J. Clin. Epidemiol. 55, 25–31.
Behari, M., Srivastava, A. K., Das, R. R., and Pandey, R. M. (2001). Neurol. Sci. 190, 49–55.
Swerdlow, R. H., Parker, W. D., Currie, L. J., et al. (2001). Parkinsonism Relat. Disord. 7, 129–133.
Shibayama, H., Sato, S., Sakata, S., et al. (2001). Parkinsonism Relat. Disord. 7(Suppl.), s101.
Lyons, K. E., Hubble, J. P., Troster, A. L., Pahwa, R., and Koller, W. C. (1998). Clin. Neuropharmacol. 21, 118–121.
Tison, F., Dartigues, J. F., Dubes, L., Zuber, M., Alperovitch, A., and Henry, P. (1994). Acta Neurol. Scand. 90, 111–115.
de Rijk, M. C., Breteler, M. M., Graveland, G. A., et al. (1995). Neurology 45, 2143–2146.
de Rijk, M. C., Launer, L. J., Berger, K., et al. (2000). Neurology 54(Suppl. 5), S21-S23.
Horstink, M. W. and Bloem, B. R. (2002). J. Neurol. Neurosurg. Psychiatry 72, 276–277.
Lucking, C. B., Durr, A., Bonifati, V., et al. (2000). N. Engl. J. Med. 342, 1560–1567.
Nausieda, P. A., Bieliauskas, L. A., Bacon, L. D., Hagerty, M., Koller, W. C., and Glantz, R. N. (1983). Neurology 33, 750–754.
Schipper, H. M. (1986). Neurol. Clin. 4, 721–751.
Leys, D., Destee, A., Petit, H., and Warot, P. (1987). J. Neurol. 235, 46–48.
Cardoso, F. (2002). Arch. Neurol. 59, 868–870.
Pelletier, J., Cabanot, C., Levrier, O., Thuillier, J. N., and Cherif, A. A. (1997). Rev. Neurol. 153, 393–397.
Omdal, R. and Roalso, S. (1992). Acta Neurol. Scand. 86, 219, 220.
Mathur, A. K. and Gatter, R. A. (1988). J. Rheumatol. 15, 1042, 1043.
Iskander, M. K. and Khan, M. (1989). J. Rheumatol. 16, 850, 851.
Asherson, R. A., Gibson, D. G., Evans, D. W., Baguley, E., and Hughes, G. R. (1988). Ann. Rheum. Dis. 47, 947–953.
Sandyk, R. (1989). Int. J. Neurosci. 45, 119–122.
Fernandez, H. H. and Lapane, K. L. (2000). Mov. Disord. 15, 1119–1124.
Tsang, K. L., Ho, S. L., and Lo, S. K. (2000). Neurology 54, 2292–2298.
Blanchet, P. J., Fang, J., Hyland, K., Arnold, L. A., Mouradian, M. M., and Chase, T. N. (1999). Neurology 53, 91–95.
Strijks, E., Kremer, J. A., and Horstink, M. W. (1999). Clin. Neuropharmacol. 22, 93–97.
Saunders-Pullman, R., Gordon-Elliott, J., Parides, M., Fahn, S., Saunders, H. R., and Bressman, S. (1999). Neurology 52, 1417–1421.
Benedetti, M. D., Maraganore, D. M., Bower, J. H., et al. (2001). Mov. Disord. 16, 830–837.
Marder, K., Tang, M. X., Alfaro, B., et al. (1998). Neurology 50, 1141–1143.
Gonera, E. G., van’t Hof, M., Berger, H. J., van Weel, C., and Horstink, M. W. (1997). Mov. Disord. 12, 871–876.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dluzen, D.E., Horstink, M.W.I.M. Estrogen as neuroprotectant of nigrostriatal dopaminergic system. Endocr 21, 67–75 (2003). https://doi.org/10.1385/ENDO:21:1:67
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:21:1:67